“…These enrichment analyses were used to explore the molecular mechanisms of enriched genes involved in the occurrence and advancement of HD. Signaling pathways include signaling by GPCR [56] [99], EGFR (epidermal growth factor receptor) [100], ABCA1 [101], CRHR2 [102], RND3 [103], COMT (catechol-Omethyltransferase) [104] and SMAD9 [105] plays an important role in the pathogenesis of hypertension. Studies have revealed that NEUROD4 [106], SOX10 [107], MOG (myelin oligodendrocyte glycoprotein) [108], NR5A2 [109], GLRA3 [110], FA2H [111], SERPINA [112], HOXB9 [113], TGM2 [114], LRRK2 [115], ROS1 [116] NKX6-1 [141], SLC22A3 [142], CADM2 [143], FREM1 [144], TWIST2 [145], WNT16 [146], KISS1 [147], TMEM176B [148], MYL9 [149], IL7R [150], MBP (myelin basic protein) [151], GPR37 [152], ACAN (aggrecan) [153], SHH (sonic hedgehog signaling molecule) [154], HOXD9 [155], PROK1 [156], AGTR1 [157], TIE1 [158], P2RX7 [159], NTSR1 [160], VTN (vitronectin) [161], SIRT2 [162], RBP4 [163] [178], HLA-DRB1 [179], NKX2-3 [180], CD74 [92], HLA-DRA [181], VWF (von Willebrand factor)…”